<?xml version="1.0" encoding="UTF-8"?>
<p class="p">Poor permeability is considered most definitely one of the main hurdles in antibacterial drug discovery
 <xref rid="CIT0016" ref-type="bibr" class="xref">
  <sup class="sup">16</sup>
 </xref>
 <sup class="sup">,</sup>
 <xref rid="CIT0017" ref-type="bibr" class="xref">
  <sup class="sup">17</sup>
 </xref>. While hydrophobic drugs, such as macrolides, pass across the outer membrane lipid bilayer, small hydrophilic drugs, such as β-lactams, use preferentially porins to accumulate inside the cell
 <xref rid="CIT0017" ref-type="bibr" class="xref">
  <sup class="sup">17–19</sup>
 </xref>. Actually, difference in membrane composition, and therefore different permeability, is at the base of the antibacterial selectivity toward Gram-positive and Gram-negative bacteria. A retrospective analysis has shown that antibacterials, in general, present higher molecular weight and lower lipophilicity than non-antiinfective drugs. In addition, Gram-negative active compounds tend to present lower molecular weight and higher polarity compared to the agents active against Gram-positive bacteria
 <xref rid="CIT0016" ref-type="bibr" class="xref">
  <sup class="sup">16</sup>
 </xref>
 <sup class="sup">,</sup>
 <xref rid="CIT0017" ref-type="bibr" class="xref">
  <sup class="sup">17</sup>
 </xref>
 <sup class="sup">,</sup>
 <xref rid="CIT0020" ref-type="bibr" class="xref">
  <sup class="sup">20</sup>
 </xref>
 <sup class="sup">,</sup>
 <xref rid="CIT0021" ref-type="bibr" class="xref">
  <sup class="sup">21</sup>
 </xref>.
</p>
